Investments
16Portfolio Exits
7Partners & Customers
2About California Institute of Regenerative Medicine
California Institute of Regenerative Medicine (CIRM) was created by the people of California to accelerate stem cell treatments to patients with unmet medical needs, and act with a sense of urgency to succeed in that mission. To meet this challenge, CIRM actively partners with both academia and industry in a hands-on, entrepreneurial environment to fast track the development of today's most promising stem cell technologies.
California Institute of Regenerative Medicine Headquarters Location
210 King Street
San Francisco, California, 94107,
United States
415-396-9100
Latest California Institute of Regenerative Medicine News
Oct 20, 2021
2010年 University of California San Diego 博士研究員 California Institute of Regenerative Medicine リサーチフェロー 2013年 University of Georgia, Department of Biochemistry & Molecular Biology 助教授 2019年 University of Georgia, Department of Biochemistry & Molecular Biology 准教授 2019年 京都大学ウイルス・再生医科学研究所 教授
California Institute of Regenerative Medicine Investments
16 Investments
California Institute of Regenerative Medicine has made 16 investments. Their latest investment was in BioEclipse Therapeutics as part of their Grant on April 4, 2022.
California Institute of Regenerative Medicine Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
4/26/2022 | Grant | BioEclipse Therapeutics | $8M | Yes | 1 | |
9/24/2021 | Grant | The Lundquist Institute for Biomedical Innovation | $5M | Yes | 1 | |
5/1/2020 | Grant | ExCellThera | $1.5M | Yes | 2 | |
12/6/2017 | Grant | |||||
10/11/2017 | Grant - III |
Date | 4/26/2022 | 9/24/2021 | 5/1/2020 | 12/6/2017 | 10/11/2017 |
|---|---|---|---|---|---|
Round | Grant | Grant | Grant | Grant | Grant - III |
Company | BioEclipse Therapeutics | The Lundquist Institute for Biomedical Innovation | ExCellThera | ||
Amount | $8M | $5M | $1.5M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | |||||
Sources | 1 | 1 | 2 |
California Institute of Regenerative Medicine Portfolio Exits
7 Portfolio Exits
California Institute of Regenerative Medicine has 7 portfolio exits. Their latest portfolio exit was ViaCyte on July 11, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
7/11/2022 | Acquired | 9 | |||
Date | 7/11/2022 | ||||
|---|---|---|---|---|---|
Exit | Acquired | ||||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 9 |
California Institute of Regenerative Medicine Partners & Customers
2 Partners and customers
California Institute of Regenerative Medicine has 2 strategic partners and customers. California Institute of Regenerative Medicine recently partnered with Quintiles Transnational on June 6, 2016.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
6/15/2016 | Partner | United States | CIRM Creates First of its Kind Center to Accelerate Stem Cell Development. `` This partnership with Quintiles Transnational Inc. means that CIRM projects will not only be accelerated , but that CIRM will also realize a reasonable financial return on this investment . '' | 2 | |
Partner |
Date | 6/15/2016 | |
|---|---|---|
Type | Partner | Partner |
Business Partner | ||
Country | United States | |
News Snippet | CIRM Creates First of its Kind Center to Accelerate Stem Cell Development. `` This partnership with Quintiles Transnational Inc. means that CIRM projects will not only be accelerated , but that CIRM will also realize a reasonable financial return on this investment . '' | |
Sources | 2 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.